185 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28249207	78	Discovery of benzofuran-3(2H)-one derivatives as novel DRAK2 inhibitors that protect islet?-cells from apoptosis.	East China Normal University
28692292	73	Discovery of Potent and Selective Inhibitors of Cdc2-Like Kinase 1 (CLK1) as a New Class of Autophagy Inducers.	Sichuan University and Collaborative Innovation Center For Biotherapy
27789138	355	Synthesis and optimization of furano[3,2-d]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors.	Abbvie Bioresearch Center
28005359	66	Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines.	Newcastle University
27940419	31	Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleton - A possible way to dual VEGFR2 TK/CLK ligands.	Comenius University In Bratislava
28280261	84	Non-kinase targets of protein kinase inhibitors.	The University of Sydney
27816515	143	Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors.	Merck
27171036	164	Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.	University of Nebraska Medical Center
27363938	2	A chromatography-free isolation of rohitukine from leaves of Dysoxylum binectariferum: Evaluation for in vitro cytotoxicity, Cdk inhibition and physicochemical properties.	India Academy of Scientific & Innovative Research (Acsir)
27078757	121	Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R).	Astrazeneca
26985305	34	Development of a Potent, Specific CDK8 Kinase Inhibitor Which Phenocopies CDK8/19 Knockout Cells.	Genentech
26851505	65	5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.	Palack£
25914804	20	Discovery of novel 5-fluoro-N(2),N(4)-diphenylpyrimidine-2,4-diamines as potent inhibitors against CDK2 and CDK9.	Chinese Academy of Medical Sciences and Peking Union Medical College
26408454	51	An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis.	University of South Australia
26349627	133	Discovery and SAR of novel pyrazolo[1,5-a]pyrimidines as inhibitors of CDK9.	The University of Melbourne
25262942	189	Rational design of inhibitors of the bacterial cell wall synthetic enzyme GlmU using virtual screening and lead-hopping.	Astrazeneca
25730262	195	10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A.	Technische Universit£T Braunschweig
24798019	30	Acridone alkaloids from Glycosmis chlorosperma as DYRK1A inhibitors.	Institut De Chimie Des Substances Naturelles
24973661	10	9- and 11-substituted 4-azapaullones are potent and selective inhibitors of African trypanosoma.	Technische Universit£T Braunschweig
24793884	151	Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors.	Amgen
24742150	101	Synthesis and evaluation of phosphorus containing, specific CDK9/CycT1 inhibitors.	Vichem Chemie
24120542	90	The optimization of aminooxadiazoles as orally active inhibitors of Cdc7.	Amgen
23454515	66	Chemical synthesis and biological validation of immobilized protein kinase inhibitory Leucettines.	Universit£
24185375	76	Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents.	University of Nottingham
23994326	9	6-Cyclohexylmethoxy-5-(cyano-NNO-azoxy)pyrimidine-4-amine: a new scaffold endowed with potent CDK2 inhibitory activity.	Universit£
23937569	22	Selectivity data: assessment, predictions, concordance, and implications.	Eli Lilly
23867602	122	Lead identification of novel and selective TYK2 inhibitors.	Genentech
23829517	30	A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors.	Palack£
23726345	41	Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.	Boehringer Ingelheim (Canada)
23600925	12	Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.	H. Lee Moffitt Cancer Center and Research Institute
23301767	154	Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities.	University of Nottingham
22770608	35	Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases.	Palack£
23252711	46	Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.	University of Oxford
20146435	60	Design, synthesis, and evaluation of 2-methyl- and 2-amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors.	University of St. Andrews
22982525	32	Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors.	TBA
22726925	216	Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.	Cellzome
22998443	69	Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.	Cnrs
23085105	30	Synthesis and biological evaluation of imidazo[4,5-b]pyridine and 4-heteroaryl-pyrimidine derivatives as anti-cancer agents.	University of Nottingham
22339472	148	Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arth	S Bio
22465635	95	Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families.	Abbott Laboratories
18469809	41	A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity.	Nerviano Medical Sciences Oncology
20138512	82	Discovery of potent and bioavailable GSK-3beta inhibitors.	Roche Palo Alto
20153204	109	Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.	Nerviano Medical Sciences
18183025	12060	A quantitative analysis of kinase inhibitor selectivity.	Ambit Biosciences
18077363	314	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.	University of Oxford
18232649	60	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex.	University of Oxford
17935989	146	Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics.	Abbott Laboratories
22225635	5	Synthesis and biological evaluation of benzo[d]imidazole derivatives as potential anti-cancer agents.	University of Nottingham
22014550	337	Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).	Ansaris
21982796	108	Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors.	The Institute of Cancer Research
22037378	31824	Comprehensive analysis of kinase inhibitor selectivity.	Ambit Biosciences
21907583	48	CNS and antimalarial activity of synthetic meridianin and psammopemmin analogs.	University of South Florida
21777997	1	The selective P-TEFb inhibitor CAN508 targets angiogenesis.	Palack£
21080703	20	A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration.	Imperial College
20621478	37	Concise synthesis and CDK/GSK inhibitory activity of the missing 9-azapaullones.	Trinity College
21417417	8	Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity.	Palacky£? University and Institute of Experimental Botany Ascr
20873740	111	Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding.	Nerviano Medical Sciences
19654408	2521	AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).	Ambit Biosciences
20462263	127	Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors.	Cyclacel
18842409	28	A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties.	Sunesis Pharmaceuticals
19555113	45	Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships.	Nerviano Medical Sciences
19338355	104	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.	University of Illinois At Chicago
18926699	30	Modifications of the isonipecotic acid fragment of SNS-032: analogs with improved permeability and lower efflux ratio.	Sunesis Pharmaceuticals
16682184	25	Identification of potent 5-pyrimidinyl-2-aminothiazole CDK4, 6 inhibitors with significant selectivity over CDK1, 2, 5, 7, and 9.	Banyu Tsukuba Research Institute
32284225	6	Synthesis and evaluation of 7-azaindole derivatives bearing benzocycloalkanone motifs as protein kinase inhibitors.	North-West University
30639897	48	Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.	The First Affiliated Hospital of Zhengzhou University
32502343	79	Discovery of MFH290: A Potent and Highly Selective Covalent Inhibitor for Cyclin-Dependent Kinase 12/13.	Harvard Medical School
32150405	75	CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?	Lebanese American University
32129996	166	Discovery and SARs of 5-Chloro-	Anhui Medical University
31846828	2	Development of selective mono or dual PROTAC degrader probe of CDK isoforms.	Sichuan University and Collaborative Innovation Center of Biotherapy
31757666	314	Discovery and optimization of heteroaryl piperazines as potent and selective PI3K? inhibitors.	Merck
30665142	41	Cink4T, a quinazolinone-based dual inhibitor of Cdk4 and tubulin polymerization, identified via ligand-based virtual screening, for efficient anticancer therapy.	De Montfort University
27491711	422	Optimization of microtubule affinity regulating kinase (MARK) inhibitors with improved physical properties.	Merck And
27355974	198	Discovery and Pharmacokinetic and Pharmacological Properties of the Potent and Selective MET Kinase Inhibitor 1-{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl]benzothiazol-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844).	Sanofi-Aventis Germany
31477350	80	Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).	Eli Lilly
31514062	80	Recent advances in the development of cyclin-dependent kinase 7 inhibitors.	Tianjin University of Science and Technology
31098000	63	Discovery of CDK5 Inhibitors through Structure-Guided Approach.	University of South Australia
30943029	59	3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.	Palack£
31859507	212	Discovery of BAY-985, a Highly Selective TBK1/IKK? Inhibitor.	Bayer
31693351	473	Discovery of 4	TBA
31376566	19	Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer.	Nankai University
31381325	46	Discovery of Inhibitors of Aurora/PLK Targets as Anticancer Agents.	Chengdu University
30733087	53	A review on flavones targeting serine/threonine protein kinases for potential anticancer drugs.	China Pharmaceutical University
31238183	13	Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity.	China Pharmaceutical University
30978559	38	Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib.	University of Padova
30543440	86	Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.	University of South Australia Cancer Research Institute
31647655	114	Kinase Chemodiversity from the Arctic: The Breitfussins.	Uit - The Arctic University of Norway
30384048	365	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.	University of Florida
30343954	16	Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy.	Eppley Institute For Research In Cancer and Allied Diseases
31622099	44	Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88	Astrazeneca
31526603	379	Structure-based rational design of staurosporine-based fluorescent probe with broad-ranging kinase affinity for kinase panel application.	Takeda Pharmaceutical
31629164	82	3-Hydrazinoisatin-based benzenesulfonamides as novel carbonic anhydrase inhibitors endowed with anticancer activity: Synthesis, in vitro biological evaluation and in silico insights.	Egyptian Russian University
30234987	232	How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?	Palack£
28156111	214	Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation.	University of South Australia
27002243	42	Discovery of a Selective and Potent Inhibitor of Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 (MNK1/2) Utilizing Structure-Based Drug Design.	Novartis Institutes For Biomedical Research
25908517	14	Discovery of novel indirubin-3'-monoxime derivatives as potent inhibitors against CDK2 and CDK9.	Chinese Academy of Medical Sciences and Peking Union Medical College
25835357	22	Novel arylazopyrazole inhibitors of cyclin-dependent kinases.	Palack�
25368960	17	Biphenyl-4-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-methylamide (CA224), a nonplanar analogue of fascaplysin, inhibits Cdk4 and tubulin polymerization: evaluation of in vitro and in vivo anticancer activity.	De Montfort University
31200237	95	Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer.	Shanghai Pharmaceuticals Holding
30199702	24	A ?-glucuronidase-responsive albumin-binding prodrug for potential selective kinase inhibitor-based cancer chemotherapy.	Universit£
29046238	17	1,3,5-Triazines: A promising scaffold for anticancer drugs development.	Universit£
28911822	24	Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.	Central University of Punjab
29985601	64	Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.	Seoul National University
29398441	111	Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4.	Astrazeneca
30253346	46	Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.	Chinese Academy of Sciences
30026041	139	Synthesis and anticancer activity of novel bisindolylhydroxymaleimide derivatives with potent GSK-3 kinase inhibition.	University College Cork
29266937	36	Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?	University of South Australia
29459274	69	Design, synthesis and biological evaluation of tetrahydronaphthyridine derivatives as bioavailable CDK4/6 inhibitors for cancer therapy.	Shanghai Haihe Pharmaceutical
28987604	3	Discovery and synthesis of novel Wogonin derivatives with potent antitumor activity in vitro.	China Pharmaceutical University
29550093	13	Discovery of novel CDK inhibitors via scaffold hopping from CAN508.	Chinese Academy of Medical Sciences and Peking Union Medical College
29329658	63	Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma.	Semmelweis University
29273417	26	An appraisal on synthetic and pharmaceutical perspectives of pyrazolo[4,3-d]pyrimidine scaffold.	University of Kwazulu-Natal
29778892	48	Structure-based design of novel quinoxaline-2-carboxylic acids and analogues as Pim-1 inhibitors.	University of Tours
30067358	79	Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors.	Takeda Pharmaceutical
29853338	31	Design, synthesis and biological evaluation of pyrimidine derivatives as novel CDK2 inhibitors that induce apoptosis and cell cycle arrest in breast cancer cells.	Shihezi University
29853332	50	Benzofuro[3,2-d]pyrimidines inspired from cercosporamide CaPkc1 inhibitor: Synthesis and evaluation of fluconazole susceptibility restoration.	Universit£
28651979	6	Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate.	Nankai University
29370702	41	Discovery and Preclinical Development of IIIM-290, an Orally Active Potent Cyclin-Dependent Kinase Inhibitor.	Csir-Indian Institute of Integrative Medicine
28947155	34	Discovery of N-substituted 7-azaindoles as PIM1 kinase inhibitors - Part I.	Sanofi Genzyme
28830649	101	Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model.	Genentech
28827110	54	Synthesis and biological evaluation of N9-cis-cyclobutylpurine derivatives for use as cyclin-dependent kinase (CDK) inhibitors.	Korea Research Institute of Chemical Technology
27721154	660	Exploration of the imidazo[1,2-b]pyridazine scaffold as a protein kinase inhibitor.	University of Paris
29144137	60	Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model.	Csir-Indian Institute of Integrative Medicine
28302507	124	Design and synthesis of selective CDK8/19 dual inhibitors: Discovery of 4,5-dihydrothieno[3',4':3,4]benzo[1,2-d]isothiazole derivatives.	Takeda Pharmaceutical
29518312	78	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer.	Nankai University
28487075	36	N-(1H-Pyrazol-3-yl)quinazolin-4-amines as a novel class of casein kinase 1?/? inhibitors: Synthesis, biological evaluation and molecular modeling studies.	Rajiv Gandhi Proudyogiki Vishwavidyalaya
34651447	87	A patent review on SARS coronavirus main protease (3CLpro) inhibitors.	Experimental Drug Development Centre
9650799	159	[125I]Tyr10-cortistatin14 labels all five somatostatin receptors.	Novartis Pharma
19115845	39	First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery.	Nerviano Medical Sciences
19128055	24	Pyrazolo[1,5-a]-1,3,5-triazine as a purine bioisostere: access to potent cyclin-dependent kinase inhibitor (R)-roscovitine analogue.	Universite De Lyon
19007108	32	Synthetic and Crystallographic Studies of a New Inhibitor Series Targeting Bacillus anthracis Dihydrofolate Reductase.	University of Connecticut
17228885	10	New fluorescent 2-phenylindolglyoxylamide derivatives as probes targeting the peripheral-type benzodiazepine receptor: design, synthesis, and biological evaluation.	Universita Di Pisa
17064068	36	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.	Palacky University
15261277	30	Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors.	Cyclacel